Total Funding
42
Total FundingSeries A raised
Growth Score
pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases.
Joseph Patti: President & CEOPast Role: Inhibitex, Chief Scientific Officer and Senior Vice President of Research and Development
David Peabody: Founder
About the Company
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. The company identifies and selects lead vaccine candidates through its proprietary affinity optimizes those by in vitro and in vivo testing and develops them through pre-clinical and/or clinical testing
until proof of concept is achieved establishing attractive out-licensing opportunities to Pharma or Biotech partners. Collaborations and partnerships are actively pursued within the industry, academia, and the government sector through NIAID.
